Lancet Oncology 2006, 7: 379–91.CrossRefPubMed 10. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Banavida B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic

drugs. Cancer Biother Radiopharm 1997, 12: 177–186.CrossRefPubMed 11. Jaffe ES, Harris NL, Vardiman J, Stein H: Pathology and genetics: neoplasms of the hematopoietic and lymphoid tissues. In World Health Organization Classification of Tumours. Edited by: Kleihues P, Sobin LH. Lyon: IARC Press; 2001:237–53. 12. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84: 1361–92.PubMed 13. McKelvey EM, Gottlieb selleck chemical JA, Wilson check details HE, Haut A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moon TE: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38: 1484–93.CrossRefPubMed 14. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CharlesL, Cantor ScottB, Crawford Jeffrey, Cross ScottJ, Demetri George, Desch ChristopherE, Pizzo PhilipA, Schiffer CharlesA, Schwartzberg Lee, Somerfield MarkR, Somlo George, Wade JamesC, Wade JamesL, Winn

RodgerJ, Wozniak AntoinetteJ, Wolff AntonioC: 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 1:

3187–205.CrossRef 15. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 1972, 34: 187–220. 16. Lee KW, Kim DY, Yun T, Kim DW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK: Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003, 98: 2651–6.CrossRefPubMed 17. Bupivacaine Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23: 3530–40.CrossRefPubMed 18. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61: 5137–44.PubMed 19. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. Journal of Clin Oncol 2004, 22: 4302–11.CrossRef 20.